We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

0000950123-24-003803 Sample Contracts

OFFICE LEASE
Office Lease • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California

This Office Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between HSPF LA JOLLA COMMONS I INVESTORS LLC, a Delaware limited liability company (“Landlord”), and ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Tenant”).

SELECTED PRODUCT LICENSE AGREEMENT (AB-201)
Selected Product License Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

THIS SELECTED PRODUCT LICENSE AGREEMENT (the “Agreement”) is made and entered into as of September 29, 2020 (the “Effective Date”) by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having a place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121, USA, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of Korea. Artiva and GCLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

Private & Confidential
Employment Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

On behalf of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start date, which will be on December 31, 2021 (the “Start Date”).

Dr. Heather Raymon Private & Confidential
Employment Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

On behalf of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start date, which will be on or around October 22, 2020 (the “Start Date”).

CONSULTING AGREEMENT
Consulting Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California

THIS CONSULTING AGREEMENT (the “Agreement”) is sat by and between ARTIVA BIOTHERAPEUTICS, INC. (“Company”) and MEF CONSULTING LLC, a Limited liability company (“Consultant”), effective as of April 3, 2023 (the “Effective Date”).

Re: Employment Offer Letter
Employment Offer Letter • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

On behalf of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start date, September 16th, 2020.

Agreement Confidential QA Controlled Document Master Agreement for Manufacturing Services March 16, 2020 / DCR001 AGR001.01
Master Agreement for Manufacturing Services • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Amendment No. 1 to Option and License Agreement
Option and License Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

This Amendment No. 1 (this “Amendment”), effective as of June 23, 2020, amends certain provisions of the Option and License Agreement dated September 4, 2019, between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having its principal place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121 and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of South Korea (hereinafter the “Original Agreement”).

OPTION AND LICENSE AGREEMENT
Option and License Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York

THIS OPTION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of September 4, 2019 (the “Effective Date”) by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having a place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121, USA, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of South Korea. Artiva and GCLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

MASTER RESEARCH SERVICES AGREEMENT (For Selected Products)
Master Research Services Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York

THIS MASTER RESEARCH SERVICES AGREEMENT (the “Agreement”) is made as of August 3, 2020 (the “Effective Date”), by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation, having an address of 4747 Executive Drive, Suite 1150, San Diego, CA 92121 (“Artiva”), and GREEN CROSS LABCELL CORPORATION, a Korean corporation, with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of Korea (“GCLC”).

Omnibus Amendment
Omnibus Amendment • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

This Omnibus Amendment (this “Amendment”), effective as of February 3, 2022, is entered into by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having its principal place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121 and GC CELL CORPORATION (F/K/A GREEN CROSS LABCELL CORPORATION), a Korean corporation (“GC Cell” or “GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 16924, Republic of South Korea.

Re: Employment Offer Letter
Employment Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

On behalf of the Board of Directors of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms are contingent upon Board approval, and will be effective as of your start date, which will be on January 1, 2021 (the “Start Date”).

FIRST AMENDMENT TO LICENSE AGREEMENT
License Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

THIS FIRST AMENDMENT TO LICENSE AGREEMENT (this “First Amendment”) is made as of May 9, 2022, by and between ARE-SD REGION NO. 37, LLC, a Delaware limited liability company (“Licensor”), and ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Licensee”).

Re: Separation Agreement
Separation Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

This letter sets forth the substance of the separation agreement (the “Agreement”) that Artiva Biotherapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition.

Michael Faerm Re: Separation Agreement Dear Mike:
Separation Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

This letter sets forth the substance of the separation agreement (the “Agreement”) that Artiva Biotherapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition.

Amendment No. 1 to Master Agreement for Manufacturing Services
Master Agreement for Manufacturing Services • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

This Amendment No. 1 (this “Amendment”), effective as of June 16, 2020, amends certain provisions of the Master Agreement for Manufacturing Services dated March 16, 2020, between Artiva Biotherapeutics, Inc. (“Company”), having its principal place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121 and Green Cross Cell Corporation, a Korean corporation (“Manufacturer”), with its principal place of business located at 107, lhyeon-ro 30 beon-gil, Giheung- gu, Yongin-si, Gyeonggi-do, 16924, Republic of South Korea (hereinafter the “Original Agreement”).

Amendment No. 1 to Consulting Agreement
Consulting Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

This Amendment No. 1 (the “Amendment”), effective as of October 3, 2023, amends certain provisions of the Consulting Agreement dated April 3, 2023 (the “Agreement”), between Artiva Biotherapeutics, Inc. (“Company”), having its principal place of business at 5505 Morehouse Drive, Suite 100, San Diego, CA 92121 and MEF Consulting LLC (“Consultant”).

Amendment No. 1 to Consulting Agreement
Consulting Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

This Amendment No. 1 (the “Amendment”), effective as of September 1, 2023, amends certain provisions of the Consulting Agreement dated March 31, 2023 (the “Agreement”), between Artiva Biotherapeutics, Inc. (“Company”), having its principal place of business at 5505 Morehouse Drive, Suite 100, San Diego, CA 92121 and Peter Flynn (“Consultant”).